The efficacy of delavirdine was found to be lower than other FDA approved NNRTIs, therefore, the US department of health and Human Services recommended its use not as a part of initial therapy but in combination with other drugs. The molecular assemblage of delavirdine was concurrently also altered by rearranging its vital fragments into altogether a different molecular setting and by synthesized enone ester formation of new delavirdine analogue could be possible.